Weekly Research Analysts’ Ratings Changes for Castle Biosciences (CSTL)

A number of firms have modified their ratings and price targets on shares of Castle Biosciences (NASDAQ: CSTL) recently:

• 5/13/2026 – Castle Biosciences had its price target lowered by BTIG Research from $50.00 to $40.00. They now have a “buy” rating on the stock.
• 5/9/2026 – Castle Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/7/2026 – Castle Biosciences was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.
• 5/7/2026 – Castle Biosciences had its price target lowered by Robert W. Baird from $44.00 to $43.00. They now have an “outperform” rating on the stock.
• 4/27/2026 – Castle Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
• 4/20/2026 – Castle Biosciences had its price target lowered by Canaccord Genuity Group Inc. from $50.00 to $40.00. They now have a “buy” rating on the stock.

Insider Activity at Castle Biosciences

In related news, Director G Bradley Cole sold 7,403 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $28.47, for a total transaction of $210,763.41. Following the sale, the director owned 19,309 shares of the company’s stock, valued at approximately $549,727.23. The trade was a 27.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Derek J. Maetzold sold 3,622 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $22.15, for a total transaction of $80,227.30. Following the sale, the insider directly owned 2,224 shares in the company, valued at approximately $49,261.60. This represents a 61.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 84,411 shares of company stock worth $2,166,211 in the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.